Time to Significant Benefit of Finerenone in Patients with Heart Failure | JACC | HFSA 2024

Michelle Kittleson, MD, FACC, JACC Associate Editor and Muthiah Vaduganathan, MD discuss findings from the FINEARTS-HF Trial -- regarding the timing of clinical benefits from finerenone in heart failure patients. The trial showed that finerenone significantly reduced worsening heart failure events and cardiovascular death, with statistical significance observed within one month of treatment initiation. Dr. Vaduganathan emphasizes that while finerenone appears effective across ejection fraction spectra, practical considerations and cost may influence prescribing decisions, highlighting the need for further research comparing it to other mineralocorticoid receptor antagonists. Vaduganathan emphasizes that while finerenone appears effective across ejection fraction spectra, practical considerations and cost may influence prescribing decisions, highlighting the need for further research comparing it to other mineralocorticoid receptor antagonists. Related content: https://www.jacc.org/doi/10.1016/j.ja... https://www.jacc.org/ #HFSA #JACC#jaccjournals #FINEARTS #Finerenone